SARM-S4 and metabolites detection in sports drug testing: A case report

Forensic Science International

Volumn 213, Issue 1-3, 2011, Pages 104-108

  Grata, Elia ^a   Perrenoud, Laurent ^a   Saugy, Martial ^a   Baume, Norbert ^a  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

Doping; Mass spectrometry; SARM; UHPLC QTOF MS; Urine

Indexed keywords

DRUG METABOLITE; SELECTIVE ANDROGEN RECEPTOR MODULATOR;

ARTICLE; CONTROLLED STUDY; DOPING; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; SPORT; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

EID: 80655149081     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.07.014     Document Type: Article

References (21)

1. Dalton J.T., Mukherjee A., Zhu Z., Kirkovsky L., Miller D.D. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 1998, 1-4.
2. Chen J., Kim J., Dalton J.T. Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. 2005, 173-188.
3. Mohler M.L., Bohl C.E., Jones A., Coss C.C., Narayanan R., He Y., Hwang D.J., Dalton J.T., Miller D.D. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 2009, 3597-3617.
4. Thevis M., Schanzer W. Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb. Exp. Pharmacol. 2010, 99-126.
5. Gao W., Kearbey J.D., Nair V.A., Chung K., Parlow A.F., Miller D.D., Dalton J.T. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004, 5420-5428.
6. Gao W., Reiser P.J., Coss C.C., Phelps M.A., Kearbey J.D., Miller D.D., Dalton J.T. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 4887-4897.
7. Bhasin S., Calof O.M., Storer T.W., Lee M.L., Mazer N.A., Jasuja R., Montori V.M., Gao W., Dalton J.T. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat. Clin. Pract. Endocrinol. Metab. 2006, 146-159.
8. Bhasin S., Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr. Opin. Clin. Nutr. Metab. Care 2009, 232-240.
9. Yin D., Gao W., Kearbey J.D., Xu H., Chung K., He Y., Marhefka C.A., Veverka K.A., Miller D.D., Dalton J.T. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 2003, 1334-1340.
10. World Anti-Doping Agency, The Prohibited List - International Standard. , 2011 (accessed 19.05.11). http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2008_EN.pdf.
11. Thevis M., Schanzer W. Mass spectrometry of selective androgen receptor modulators. J. Mass Spectrom. 2008, 865-876.
12. Kuuranne T., Leinonen A., Schanzer W., Kamber M., Kostiainen R., Thevis M. Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metab. Dispos. 2008, 571-581.
13. Thevis M., Kohler M., Thomas A., Schlorer N., Schanzer W. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 2471-2478.
14. Thevis M., Kohler M., Thomas A., Maurer J., Schlorer N., Kamber M., Schanzer W. Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Anal. Bioanal. Chem. 2008, 251-261.
15. Thevis M., Kohler M., Schlorer N., Kamber M., Kuhn A., Linscheid M.W., Schanzer W. Mass spectrometry of hydantoin-derived selective androgen receptor modulators. J. Mass Spectrom. 2008, 639-650.
16. Thevis M., Geyer H., Kamber M., Schanzer W. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test. Anal. 2009, 387-392.
17. Thevis M., Thomas A., Fussholler G., Beuck S., Geyer H., Schanzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun. Mass Spectrom. 2010, 2245-2254.
18. World Anti-Doping Agency, The World Anti-Doping Code - International Standard - Laboratories. , 2011 (accessed 23.06.11). http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_Int.Standard_Laboratories_2009_EN.pdf.
19. World Anti-Doping Agency, WADA Technical Document - TD2010IDCR. , 2011 (accessed 23.06.11). http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2010IDCRv1.0_Identification%2520Criteria%2520for%2520Qualitative%2520Assays_May%252008%25202010_EN.doc.pdf.
20. Plumb R., Castro-Perez J., Granger J., Beattie I., Joncour K., Wright A. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 2331-2337.
21. Thevis M., Kamber M., Schanzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun. Mass Spectrom. 2006, 870-876.